Acadia Pharmaceuticals Inc.

ACAD

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001070494

A

strongest fifth of 370 graded peers in healthcare

rank 65 of 370; percentile 17.3; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard

Profitability	C	percentile 53.6
Solvency	B	percentile 34.5
Growth and financing	B	percentile 22.8
Reliability	0.91 AUC	filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets	total assets $1.6B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: distress, fortress balance sheet
Inputs computable	8 of 14	
Graded from	filings received through Feb 26, 2026	254 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$21.21	2026-11-06; market equity $3.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP).

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 53.6						
Gross profitability	62.8%	32.3%		14.8	365	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	20.4%	(6.6%)	95.4	802	2025-12-31
Gross margin stability, five years	2.8 pts	2.8 pts	50.6	242	2025-12-31
Solvency, sleeve percentile 34.5					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	3.79	(0.37)	22.1	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	3.83x	2.94x	46.8	828	2025-12-31
Growth and financing, sleeve percentile 22.8					
Revenue growth, three-year compound	27.5%	10.0%	24.3	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	38.6%	2.2%	11.4	696	2025-12-31
Net share issuance, one year	2.2%	2.5%	32.8	630	2026-02-18

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
60	Vertex Pharmaceuticals Inc. MA (VRTX)	16.0	A	
61	Ensign Group, Inc. (ENSG)	16.3	A	fortress balance sheet
62	InnovAge Holding Corp. (INNV)	16.5	A	fortress balance sheet
63	Natures Sunshine Products Inc. (NATR)	16.8	A	fortress balance sheet
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.1	A	
65	Acadia Pharmaceuticals Inc. (ACAD)	17.3	A	
66	Aurinia Pharmaceuticals Inc. (AUPH)	17.6	A/B	
67	Definium Therapeutics, Inc. (DFTX)	17.9	A/B	dilution
68	UFP Technologies Inc. (UFPT)	18.2	A/B	
69	Conmed Corp. (CNMD)	18.4	A/B	
70	Dexcom Inc. (DXCM)	18.7	A/B	fortress balance sheet

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(11.2%)	(2.1%)	43
Distance from 52-week high	(30.6%)	(30.5%)	50
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	2.9%	(1.0%)	69

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.38	0.29	59
Sales to price	0.29	0.30	48
Composite equity issuance, five years	7.7%	21.4%	36
Relative strength against the sector, log excess return	(0.29)	(0.19)	43

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$322.4M
Operating cash flow, four quarters	$97.5M
Months of runway	not finite
Days since last periodic filing	2 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$35.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2025-12-31	2026-02-26	10-K	26-072519
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$89.0M	2025-12-31	2026-02-26	10-K	26-072519
3	assets	us-gaap:Assets	$1.6B	2025-12-31	2026-02-26	10-K	26-072519
4	net income	us-gaap:NetIncomeLoss	$391.0M	2025-12-31	2026-02-26	10-K	26-072519
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$109.8M	2025-12-31	2026-02-26	10-K	26-072519
6	assets	us-gaap:Assets	$1.2B	2024-12-31	2026-02-26	10-K	26-072519
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$957.8M	2024-12-31	2026-02-26	10-K	26-072519
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$81.8M	2024-12-31	2026-02-26	10-K	26-072519
9	gross profit	us-gaap:GrossProfit	$684.8M	2023-12-31	2024-02-28	10-K	24-021473
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$726.4M	2023-12-31	2026-02-26	10-K	26-072519
11	gross profit	us-gaap:GrossProfit	$507.1M	2022-12-31	2024-02-28	10-K	24-021473
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$517.2M	2022-12-31	2025-02-27	10-K	25-029253
13	gross profit	us-gaap:GrossProfit	$473.3M	2021-12-31	2023-02-28	10-K	23-004757
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$484.1M	2021-12-31	2024-02-28	10-K	24-021473
15	current assets	us-gaap:AssetsCurrent	$1.1B	2025-12-31	2026-02-26	10-K	26-072519
16	current liabilities	us-gaap:LiabilitiesCurrent	$277.1M	2025-12-31	2026-02-26	10-K	26-072519
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.8B	2025-12-31	2026-02-26	10-K	26-072519
18	operating income	us-gaap:OperatingIncomeLoss	$104.8M	2025-12-31	2026-02-26	10-K	26-072519
19	book equity	us-gaap:StockholdersEquity	$1.2B	2025-12-31	2026-02-26	10-K	26-072519
20	liabilities	us-gaap:Liabilities	$336.8M	2025-12-31	2026-02-26	10-K	26-072519
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.7M	2025-12-31	2026-02-26	10-K	26-072519
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$157.7M	2024-12-31	2026-02-26	10-K	26-072519
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$523,000	2024-12-31	2026-02-26	10-K	26-072519
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$16.7M	2023-12-31	2026-02-26	10-K	26-072519
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$50,000	2023-12-31	2026-02-26	10-K	26-072519
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$114.0M	2022-12-31	2025-02-27	10-K	25-029253

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2022-12-31	2025-02-27	10-K	25-029253
28	depreciation amortization	us-gaap:Depreciation	$871,000	2025-12-31	2026-02-26	10-K	26-072519
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$138.9M	2025-12-31	2026-02-26	10-K	26-072519
30	income tax	us-gaap:IncomeTaxExpenseBenefit	-$252.1M	2025-12-31	2026-02-26	10-K	26-072519
31	current assets	us-gaap:AssetsCurrent	$938.3M	2024-12-31	2026-02-26	10-K	26-072519
32	current liabilities	us-gaap:LiabilitiesCurrent	$394.9M	2024-12-31	2026-02-26	10-K	26-072519
33	assets	us-gaap:Assets	$749.0M	2023-12-31	2025-02-27	10-K	25-029253
34	assets	us-gaap:Assets	$587.8M	2022-12-31	2024-02-28	10-K	24-021473
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	170,494,613	2026-02-18	2026-02-26	10-K	26-072519
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	166,788,517	2025-02-18	2025-02-27	10-K	25-029253

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.